Promethera Biosciences and Shibuya Announce Strategic Collaboration to Establish Breakthrough Cell Therapy Manufacturing Platform

05-Oct-2017 Intellasia | BusinessWire | 2:30 PM Print This Post

MONT-SAINT-GUIBERT, Belgium & KANAZAWA, ISHIKAWA, Japan–(BUSINESS WIRE)–Promethera Biosciences SA, a global innovator in cell-based medicines,
and Shibuya Corporation (6340:Tokyo Stock Exchange) announced today a
strategic collaboration to establish a high-throughput, commercial-scale
and clinical-grade cell therapy and regenerative medicine manufacturing
platform. For Promethera, the collaboration will act as a cornerstone to
optimize and expand the manufacturing capabilities for its current and
future portfolio of liver-derived cell therapies to treat Non-Alcoholic
Steatohepatitis (NASH), acute-on-chronic liver-failure (ACLF) and other
indications. For Shibuya, the deal represents a significant step towards
bringing the company’s expertise to the European market and becoming a
global leader in the manufacturing of regenerative medicine products.
Both parties will combine their capabilities and expertise to establish
a first-in-class manufacturing facility starting at Promethera’s new
premises in Gosselies, Belgium. Financial terms of the agreement were
not disclosed.

“Japan in particular is leading the charge when it comes to making the
cell therapy revolution a reality. It is widely accepted
that commercial manufacturing in the cell therapy
space represents a key hurdle to overcome in this regard. We therefore
welcome the opportunity to conquer this challenge together with our
partners from Shibuya Corporation,“ commented Dr. John Tchelingerian,
CEO of Promethera Biosciences. “Once successfully established, starting
in Europe, the joint production platform will significantly increase our
and our partners’ manufacturing capabilities in the cell therapy space
reinforcing our claim to offer treatment to potentially thousands
of patients from one donated liver.”

“Research, clinical studies and market supply in the emerging sector of
cell therapy and regenerative medicine require large scale cell
cultivation at a reasonable cost while adhering to highest quality and
safety standards of various types of stem cells. We are very pleased to
team up with Promethera as one of the key innovators and the pioneer in
the liver-derived cell therapy arena to establish a joint system that is
capable of consistently meeting this demand,“ commented Hidetoshi
Shibuya, Managing Director Shibuya Corporation and CEO Shibuya Hoppmann

Shibuya has manufactured and installed a variety of aseptic systems and
equipment for hospitals and universities which includes cell culture
isolators, robotic cell culture isolators and 3D bio printers. All
systems are suited for very high level disinfection processes and
operate without direct human intervention. This allows Shibuya to
achieve unprecedented control over cell processing and culture
conditions to ensure highest product quality and safety standards.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver cell-based
medicines whose mission is to help patients overcome acute and chronic
liver diseases. Our lead clinical program, derived from our patented
cell technology platform HepaStem, is designed to benefit from its
immune-modulatory and anti-fibrotic properties. We are a team of
international experts operating out of R&D and GMP facilities in
Mont-Saint-Guibert, Belgium, and Durham, NC, USA.

Promethera®, HepaStem®, H2stem®, Cytonet®, Heparesc® are all registered
trademarks of the PROMETHERA group.

About Shibuya Corporation

Shibuya was founded in 1931 and is the largest packaging system
manufacturer in Japan. Shibuya is a publicly held company and listed on
the Tokyo Stock Exchange. The company has about 3,200 employees, and its
annual sales is more than 90 billion yen. Shibuya offers reliable, world
leading technologies to many industries, including pharmaceutical,
cosmetic, household, food and beverage, confectionery, personal care and


Promethera Biosciences SA
Alexandra Schiettekatte
[email protected]

MacDougall Communications
Schweitzer or Mario Brkulj
+49 89 2424 3494 or +49 175 501 0575
[email protected]


Category: BusinessWire, PRAsia

Print This Post